Q&A with Dr. Shawn Rose
Autoimmune Innovation Merits a “Greater Sense of Urgency”
“I sat in the chair for four long hours with these large-bore needles that hurt like hell, hooked up to this noisy, clanking machine watching the blood flowing through. It was a harrowing experience. I think it’s a competitive advantage for Nkarta that our off-the-shelf allogeneic cell therapy doesn’t require leukapheresis and is a more patient-friendly approach.”
Patients First
Why Stable Research Funding and Trade Policy Matter for Patients
On the Biotech Nation podcast, Nkarta CEO Paul Hastings discusses how research funding cuts and pharmaceutical tariff increases impact patients’ access to treatments and cures.
Patients First
Our Clinical Trial Promise
Instead of asking people with serious diseases to reconstruct their lives around our studies, drug developers should be striving to design our research around their lives. Read about what Nkarta is doing to make clinical trial opportunities more accessible and equitable.
Nature
Boosted Killer Cells Show
Promise For Autoimmune Disease
“Supercharged ‘natural killer’ cells could become a potent way to reset a disordered immune system,” according to one of the world's most prestigious scientific journals.
CEO Fireside
Changing What’s Possible in Autoimmune Treatment
Nkarta CEO Paul Hastings, a lifelong patient advocate, breaks down natural killer cell therapy and how it could potentially transform the therapeutic landscape in autoimmunity.